A new probiotic bacteria called Phocaeicola dorei YGMCC0564 reduced weight gain, improved blood sugar control, and lowered cholesterol in mice fed high-fat diets, according to research published in Frontiers in Microbiology. The bacteria worked by changing gut microbiota composition and altering bile acids, which are substances that help regulate metabolism. Treated mice gained significantly less weight and showed less liver fat accumulation compared to untreated mice, with effects comparable to the prescription medication orlistat. While these results are promising, human studies are needed before this bacteria could be used as a treatment
Researchers tested a new type of probiotic bacteria called Phocaeicola dorei YGMCC0564 to see if it could help mice on high-fat diets avoid weight gain, high cholesterol, and high blood sugar. According to Gram Research analysis, the bacteria worked by changing the mix of microbes in the gut and altering bile acids, which are substances that help digest fat. The treated mice gained less weight, had better blood sugar control, and showed less fat buildup in their livers compared to mice that didn’t receive the probiotic. The bacteria appeared to work safely in animal tests, suggesting it might one day help people manage metabolic disorders without the side effects of current medications.
Key Statistics
A 2026 research article in Frontiers in Microbiology found that mice receiving Phocaeicola dorei YGMCC0564 probiotic bacteria gained significantly less weight on high-fat diets and showed improved blood sugar control compared to untreated mice.
According to the study, the probiotic bacteria reduced hepatic steatosis (fatty liver disease) and improved insulin resistance in mice, with metabolic improvements comparable to orlistat, a prescription weight-loss medication.
Gram Research analysis shows the bacteria altered gut microbiota composition and increased beneficial short-chain fatty acids while remodeling bile acid profiles, activating metabolic pathways that suppress glucose production in laboratory cell tests.
Safety testing in the 2026 study found no obvious adverse effects when Phocaeicola dorei YGMCC0564 was given to mice for 4 weeks, including in immunodeficient animals, suggesting a favorable safety profile in animal models.
The Quick Take
- What they studied: Whether a new probiotic bacteria could prevent weight gain, high blood sugar, and high cholesterol in mice fed a high-fat diet
- Who participated: Laboratory mice divided into groups: some received the new probiotic bacteria, some received a common probiotic (Lactobacillus rhamnosus GG), some received the drug orlistat, and some received no treatment while eating a high-fat diet
- Key finding: Mice that received the new probiotic bacteria gained significantly less weight, had better blood sugar control, lower cholesterol levels, and less fat in their livers compared to untreated mice on the same high-fat diet
- What it means for you: This research suggests a probiotic bacteria might help prevent metabolic problems caused by unhealthy diets, though human studies are needed before it could be used as a treatment. The bacteria appeared safe in animal testing, which is an important first step
The Research Details
Researchers created a mouse model of metabolic disease by feeding mice a high-fat diet. They divided the mice into different groups: some received the new probiotic bacteria (YGMCC0564) mixed with their food, some received a well-known probiotic for comparison, some received the weight-loss drug orlistat, and some received no special treatment. The study was designed as prevention, meaning the bacteria was given at the same time the high-fat diet started, not after problems developed.
The researchers measured many things to see if the bacteria worked: body weight and composition, blood sugar levels, cholesterol levels, liver health through microscope examination, and gene expression in the intestines. They also analyzed the bacteria living in the mice’s guts using genetic sequencing, looked at metabolites (chemical byproducts) in the feces, and measured short-chain fatty acids, which are beneficial compounds produced when bacteria digest fiber.
To test safety, the researchers gave the bacteria to both normal mice and mice with weakened immune systems in short-term and 4-week tests. They looked for any signs of illness or organ damage. They also performed laboratory tests with human intestinal and liver cells to understand how the bacteria’s effects might work in people.
This research approach is important because it combines multiple ways of measuring results. By looking at body weight, blood chemistry, liver tissue, gut bacteria composition, and molecular signals all together, the researchers could understand not just whether the bacteria worked, but how it might work. This multi-layered approach makes the findings more convincing and helps scientists design better human studies in the future.
The study used appropriate control groups, including a well-established probiotic and a proven medication, which allows fair comparison. The researchers tested safety in two different types of mice, which strengthens confidence in the safety findings. However, this is animal research, so results may not directly apply to humans. The study was published in a peer-reviewed journal, meaning other scientists reviewed the methods and results. The exact number of mice used in each group was not specified in the abstract, which limits our ability to assess statistical power
What the Results Show
The new probiotic bacteria significantly reduced weight gain in mice fed a high-fat diet. Mice receiving YGMCC0564 gained much less weight compared to untreated mice, and their weight gain was similar to or better than mice receiving orlistat, a prescription weight-loss medication.
Blood sugar control improved substantially in the treated mice. The bacteria reduced high blood sugar levels and improved insulin resistance, meaning the mice’s bodies could use insulin more effectively to control glucose. Gene expression tests showed that the bacteria reduced the activity of genes involved in glucose production in the liver.
Cholesterol and fat metabolism improved significantly. Mice receiving the bacteria had lower cholesterol levels and reduced fatty liver disease, a condition where excess fat accumulates in liver cells and can cause serious health problems. Microscope examination of liver tissue confirmed less fat buildup in treated mice.
The bacteria changed the composition of the gut microbiota, the community of microorganisms living in the digestive system. It also increased beneficial short-chain fatty acids, which are produced when bacteria ferment fiber and have protective effects on metabolism and inflammation.
The bacteria altered bile acid profiles in the feces. Bile acids are substances produced by the liver that help digest fat. The treated mice showed increased levels of lithocholic acid and 3-beta-7-alpha-dihydroxy-5-cholestenoate, while levels of other bile acids decreased. These changes activated specific receptors in the intestines that regulate metabolism. Gene expression in the intestines increased for four key genes involved in bile acid sensing and glucose regulation: Fxr, Fgf15, Gpbar1/Tgr5, and Glp-1. Laboratory tests with human cells showed that the bile acids elevated by the bacteria activated metabolic pathways that suppress glucose production and improve glucose control. Safety testing revealed no obvious adverse effects in either acute or 4-week tests in both normal and immunodeficient mice.
Current treatments for metabolic disorders include orlistat, which blocks fat absorption, and metformin, which improves insulin sensitivity. Both medications have proven effectiveness but can cause long-term side effects like digestive problems and vitamin deficiencies. This research builds on growing evidence that gut bacteria influence metabolism through multiple pathways. Previous studies have shown that probiotics can affect weight and blood sugar, but this study provides detailed mechanisms through bile acid signaling. The multi-omics approach (analyzing multiple biological systems simultaneously) represents an advancement in understanding how probiotics work, moving beyond simple before-and-after measurements to detailed mechanistic understanding.
This study used mice, not humans, so results may not directly translate to people. Mice have different digestive systems and metabolisms than humans. The abstract does not specify the exact number of mice in each group, making it impossible to assess whether the sample size was adequate. The study was prevention-focused, meaning bacteria were given before metabolic problems developed; it’s unclear if the bacteria would help mice already suffering from these conditions. The research was conducted in laboratory settings with controlled diets and conditions, which differ from real-world human environments with varied diets and stress. Long-term effects beyond 4 weeks were not tested. The mechanism of action, while explored in laboratory cells, may work differently in living humans
The Bottom Line
Based on this animal research, the new probiotic bacteria YGMCC0564 shows promise for preventing metabolic disorders related to high-fat diets. However, human clinical trials are necessary before any recommendations can be made for people. If future human studies confirm these findings, this bacteria might offer an alternative to current medications with potentially fewer side effects. For now, established approaches like balanced diet, regular exercise, and weight management remain the evidence-based strategies for preventing metabolic disease. Confidence level: Low to Moderate (animal study only)
This research is most relevant to people at risk for metabolic syndrome, type 2 diabetes, and fatty liver disease, particularly those who struggle with high-fat diets. It may interest people seeking alternatives to medications like orlistat or metformin due to side effects. People with compromised immune systems should wait for additional safety data before considering such probiotics. This research should not replace current medical treatments or lifestyle changes recommended by doctors
In the mouse studies, metabolic improvements were observed over several weeks of probiotic supplementation. If this bacteria were eventually tested in humans, realistic timelines for seeing benefits would likely be weeks to months, similar to other probiotic interventions. However, this is speculative until human trials are conducted. Immediate effects should not be expected
Frequently Asked Questions
Can this new probiotic bacteria help me lose weight and control blood sugar?
Animal studies show Phocaeicola dorei YGMCC0564 reduced weight gain and improved blood sugar control in mice on high-fat diets. However, human clinical trials have not yet been conducted, so effectiveness in people remains unknown. Consult your doctor before considering any new supplement
How does this probiotic bacteria work to improve metabolism?
The bacteria changes the composition of gut microbes and alters bile acids, which are substances that help digest fat. These bile acids activate specific receptors in the intestines that regulate blood sugar production and glucose metabolism, based on laboratory cell studies
Is this probiotic bacteria safe to use?
Animal safety testing found no obvious adverse effects in mice over 4 weeks, including in immunodeficient animals. However, human safety data does not exist yet. Any new supplement should be discussed with a healthcare provider before use
When will this probiotic be available for people to use?
This is currently a research candidate being studied in animals. Human clinical trials would need to be conducted and approved by regulatory agencies before it could become available as a treatment or supplement. This process typically takes several years
How does this compare to current medications like metformin or orlistat?
In mice, this probiotic performed similarly to orlistat for weight control. Current medications have proven effectiveness but can cause side effects. This bacteria might offer an alternative approach, but human studies are needed to compare safety and effectiveness directly
Want to Apply This Research?
- Track weekly weight, waist circumference, and energy levels. If this probiotic becomes available for human use, users could log daily supplementation and correlate it with these measurements over 8-12 weeks to assess personal response
- Users could combine probiotic supplementation (if available) with dietary improvements by reducing high-fat foods and increasing fiber intake, which feeds beneficial gut bacteria. The app could remind users to take the supplement consistently and log meals to identify high-fat patterns
- Establish baseline measurements of weight, energy, digestion quality, and blood sugar symptoms (if applicable). Track these weekly for 12 weeks while using the probiotic. Monitor for any digestive changes or side effects. Share results with a healthcare provider to assess whether the supplement is working for your individual situation
This article summarizes animal research and is for educational purposes only. It does not constitute medical advice. Phocaeicola dorei YGMCC0564 has not been tested in humans and is not approved for human use. Do not use this information to replace professional medical advice, diagnosis, or treatment. Anyone with metabolic disorders, diabetes, high cholesterol, or concerns about weight should consult a qualified healthcare provider before starting any new supplement or treatment. This research represents early-stage findings that require human clinical trials before any therapeutic applications can be considered
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.